Ying Huang, Legend Biotech CEO

FDA lifts hold on Leg­end Biotech's fol­low-up CAR-T tar­get­ing CD4+

Leg­end Biotech got some good news last week that it di­vulged dur­ing its first quar­ter re­port Wednes­day.

Dis­cussing its earn­ings with in­vestors ear­ly this morn­ing, Leg­end re­vealed that the FDA had lift­ed a clin­i­cal hold on May 25 from its Phase I CAR-T ther­a­py tar­get­ing ma­lig­nant CD4+ T cells. Reg­u­la­tors lift­ed the hold on the pro­gram known as LB1901 af­ter it spent about three and a half months on the shelf.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.